Short Communication Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/casereports.1.003
The Global Rise of Chronic Diseases: Why Broaden the Paradigm to Include Tick-borne Illness and Environmental Toxin Exposure?
Richard Horowitz1,2,*
- 1Medical Director, Hudson Valley Healing Arts Center, Hyde Park, N.Y., USA
- 2HHS, Babesia and Tick-borne Viruses subcommittee, Washington D.C., USA
Corresponding Author
Richard Horowitz, medical@hvhac.com
Received Date: November 22, 2019
Accepted Date: December 03, 2019
Horowitz R. The Global Rise of Chronic Diseases: Why Broaden the Paradigm to Include Tick-borne Illness and Environmental Toxin Exposure? Arch Med Case Rep. 2019; 1(1):7-13.
Copyright: © 2019 Horowitz R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Exercise Benefits on Alzheimer’s Disease
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder [1] and the most common cause of human dementia, accounting for approximately 60%?80% of cases. It is estimated that more than 30 million AD patients, and the number likely to increase to over 100 million by 2050 because of the increase of the elderly population [2].
Effect of Exosomes on Alzheimer’s Disease
AD is a neurodegenerative disease characterized by progressive cognitive impairment, behavioral changes, memory loss and executive dysfunction, all of which present serious threats to the health of older people.
Virtual Reality Zoo Therapy: An Interactive Relaxing System for Alzheimer’s Disease
The number of people with Alzheimer’s disease (AD) is on the rise, yet there is no effective pharmacological treatment that can slow or reverse the disease’s progress
Investigation of B2-AR, TLR2, PICALM, and BDNF Gene Variants in Iranian Alzheimer’s Patients and Their Response to Rivastigmine
Alzheimer’s disease is the most common form of dementia with polygenic disposition occurring within various populations.
Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer’s Disease than Amyloid or Tau
Alzheimer’s disease (AD) research has long been dominated with communications regarding the amyloid hypothesis and targeting amyloid clearance through pharmacological therapies from the brain. Unfortunately, this research strategy has yielded only one new FDA-accelerated approved therapeutic for early AD, and its clinical benefit still needs to be verified. It may be time to employ a new strategy in AD therapeutics research. Hammond et al. reported that diminished uptake of glucose in the brain is a better marker for classifying AD than beta-amyloid (Aβ) or phosphorylated tau deposition.